1. |
From the Editor |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 2-2
&NA;,
Preview
|
PDF (792KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
2. |
Major step towards clarifying the risks and benefits of HRT |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 3-4
Gill Higgins,
Preview
|
PDF (1493KB)
|
|
摘要:
The first major trial to look at the cardioprotective effects of hormone replacement therapy (HRT) has provided firm evidence that HRT reduces cardiovascular risk in postmenopausal women. With the results of this trial in hand, physicians will be able to make more informed decisions regarding the use of HRT in their patients. Considerable controversy has haunted HRT since its introduction in the 1950s, as little evidence was available regarding its risks and benefits. Although the recent PEPI trial does not provide all the answers, it has begun to resolve several uncertainties, providing a platform for future studies. The results of the trial were presented at the 67th Scientific Sessions of the American Heart Association (AHA) [Dallas, US; November 1994].
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
3. |
Views in the news |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 5-5
&NA;,
Preview
|
PDF (787KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
4. |
Limited treatment options for rabies in humans |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 6-6
&NA;,
Preview
|
PDF (736KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 7-7
&NA;,
Preview
|
PDF (779KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
6. |
DNA-based vaccines hold great promise |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 8-8
&NA;,
Preview
|
PDF (755KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
7. |
Unique agent under development for CMV infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 9-10
Gill Higgins,
Preview
|
PDF (1543KB)
|
|
摘要:
Cidofovir is arousing considerable interest as a new treatment for cytomegalovirus (CMV) retinitis. The agent is unique compared with currently available therapies, as it does not require viral enzymes for activation. Accordingly, it may overcome the resistance problems encountered by the nucleoside analogues, aciclovir and ganciclovir, which arise from acquired deficiency or alteration of the enzyme thymidine kinase. Cidofovir is now in phase III trials. An account of its safety and efficacy was presented at the 4th Triennial Symposium ‘New Directions in Antiviral Chemotherapy’ [San Francisco, US; November 1994].
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
8. |
YM-934 inhibits neurogenic plasma leakage |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 10-11
&NA;,
Preview
|
PDF (1494KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 11-11
&NA;,
Preview
|
PDF (753KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
10. |
Efficacy of 'flu vaccine in elderly confirmed |
|
Inpharma Weekly,
Volume &NA;,
Issue 967,
1994,
Page 12-12
&NA;,
Preview
|
PDF (742KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|